# Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

> **NCT00426218** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 26 (estimated)

## Conditions studied

- Arthritis, Juvenile Rheumatoid

## Interventions

- **DRUG:** ACZ885

## Key facts

- **NCT ID:** NCT00426218
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-03
- **Final completion:** —
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2011-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426218, "Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00426218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*